

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6869204

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	H. LEE MOFFITT CANCER CET & RES INST	02/26/2019
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government	
<b>Street Address:</b>	NIH Division of Extramural Inventions and Technology Resources (DEITR)	
<b>Internal Address:</b>	6705 Rockledge Drive, Suite 310, MSC 7980	
<b>City:</b>	Bethesda	
<b>State/Country:</b>	MARYLAND	
<b>Postal Code:</b>	20892-7980	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Patent Number:	9221808
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(301)480-0272	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	edison@nih.gov	
<b>Correspondent Name:</b>	DIRECTOR, DEITR	
<b>Address Line 1:</b>	NIH, 6705 ROCKLEDGE DRIVE, SUITE 310	
<b>Address Line 2:</b>	MSC 7980	
<b>Address Line 4:</b>	BETHESDA, MARYLAND 20892-7980	
<b>NAME OF SUBMITTER:</b>	DIRECTOR, DEITR	
<b>SIGNATURE:</b>	/DIRECTOR, DEITR/	
<b>DATE SIGNED:</b>	08/17/2021	
<b>Total Attachments: 1</b>		
source=9221808#page1.tif		

## License to the United States Government

Sign and submit the executed document to the appropriate funding agency (e.g. upload in iEdison).

Invention Title: PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE

Inventor(s): Nicholas J. Lawrence, Roberta Pireddu, Said M. Sebti

U.S. Filing/Issue Date: Issued 12/29/2015

Patent or Application Serial No.: Patent No. 9,221,808

Grant/Contract Number(s): NIH CA067771

Foreign Applications filed/intended in (countries): \_\_\_\_\_

The invention identified above is a Subject Invention under 35 U.S.C. 200, et seq., and the Standard Patent Rights clause at 37 CFR 401.14, FAR 52.227-11 or FAR 52.227-12 (if applicable) which are included among the terms of the above identified grant or contract award from the United States Government. This document is confirmatory of:

1. The nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the invention described in any patent application and in any and all divisions, continuations, and continuations in part, and in any and all patents and re-issues granted thereon throughout the world; and
2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 21<sup>st</sup> day of February, 20 19  
By JAMES J. MULE, Ph.D. (Institutional Business Official) [Signature] (Signature)  
Title Associate Center Director, Translational Science  
For H. LEE MOFFITT CANCER CTR & RES INST  
(Grantee/Contractor Organization)

At 12902 Magnolia Drive Tampa, FL 33612  
(Business Address)